Group-sequential clinical trials with multiple co-objectives /

Saved in:
Bibliographic Details
Imprint:Japan : Springer, 2016.
Description:1 online resource (ix, 113 pages) : illustrations
Language:English
Series:SpringerBriefs in statistics, JSS research series in statistics, 2191-544X
SpringerBriefs in statistics. JSS research series in statistics.
Subject:
Format: E-Resource Book
URL for this record:http://pi.lib.uchicago.edu/1001/cat/bib/11263333
Hidden Bibliographic Details
Other authors / contributors:Hamasaki, Toshimitsu, author.
Asakura, Koko, author.
Evans, Scott R., author.
Ochiai, Toshimitsu, author.
ISBN:9784431559009
4431559000
4431558985
9784431558989
9784431558989
Digital file characteristics:text file PDF
Notes:Includes bibliographical references.
Online resource; title from PDF title page (SpringerLink, viewed June 13, 2016).
Summary:This book focuses on group sequential methods for clinical trials with co-primary endpoints based on the decision-making frameworks for: (1) rejecting the null hypothesis (stopping for efficacy), (2) rejecting the alternative hypothesis (stopping for futility), and (3) rejecting the null or alternative hypothesis (stopping for either futility or efficacy), where the trial is designed to evaluate whether the intervention is superior to the control on all endpoints. For assessing futility, there are two fundamental approaches, i.e., the decision to stop for futility based on the conditional probability of rejecting the null hypothesis, and the other based on stopping boundaries using group sequential methods. In this book, the latter approach is discussed. The book also briefly deals with the group sequential methods for clinical trials designed to evaluate whether the intervention is superior to the control on at least one endpoint. In addition, the book describes sample size recalculation and the resulting effect on power and type I error rate. The book also describes group sequential strategies for three-arm clinical trials to demonstrate the non-inferiority of experimental intervention to actively control and to assess the assay sensitivity to placebo control.
Other form:Print version: Hamasaki, Toshimitsu. Group-Sequential Clinical Trials with Multiple Co-Objectives. Tokyo : Springer Japan, ©2016 9784431558989
Standard no.:10.1007/978-4-431-55900-9

MARC

LEADER 00000cam a2200000Ii 4500
001 11263333
005 20210625184921.3
006 m o d
007 cr cnu|||unuuu
008 160603s2016 ja a ob 000 0 eng d
015 |a GBB965777  |2 bnb 
016 7 |a 019321014  |2 Uk 
019 |a 951338103  |a 951594199  |a 961863230  |a 1005836284  |a 1011906507  |a 1048156102  |a 1066473859  |a 1086543877  |a 1110968732  |a 1112580754  |a 1112796707  |a 1113588843 
020 |a 9784431559009  |q (electronic bk.) 
020 |a 4431559000  |q (electronic bk.) 
020 |a 4431558985 
020 |a 9784431558989 
020 |z 9784431558989  |q (print) 
024 7 |a 10.1007/978-4-431-55900-9  |2 doi 
035 |a (OCoLC)951103084  |z (OCoLC)951338103  |z (OCoLC)951594199  |z (OCoLC)961863230  |z (OCoLC)1005836284  |z (OCoLC)1011906507  |z (OCoLC)1048156102  |z (OCoLC)1066473859  |z (OCoLC)1086543877  |z (OCoLC)1110968732  |z (OCoLC)1112580754  |z (OCoLC)1112796707  |z (OCoLC)1113588843 
035 9 |a (OCLCCM-CC)951103084 
037 |a com.springer.onix.9784431559009  |b Springer Nature 
040 |a N$T  |b eng  |e rda  |e pn  |c N$T  |d IDEBK  |d GW5XE  |d OCLCO  |d EBLCP  |d OCLCO  |d AZU  |d OCLCF  |d YDXCP  |d OCLCO  |d N$T  |d OCLCO  |d COO  |d KSU  |d VT2  |d DEBSZ  |d IDB  |d JG0  |d IAD  |d JBG  |d ICW  |d ILO  |d ICN  |d FIE  |d OCLCQ  |d ESU  |d IOG  |d U3W  |d MERUC  |d REB  |d EZ9  |d OCLCQ  |d WYU  |d OCLCO  |d OCLCA  |d MERER  |d OCLCO  |d OCLCA  |d AUD  |d OCLCO  |d AU@  |d UKMGB  |d OCLCO  |d OCLCQ  |d DCT  |d ERF  |d UKBTH  |d OCLCQ  |d OCLCA  |d AJS 
049 |a MAIN 
050 4 |a R853.C55 
060 4 |a W 20.55.C5 
072 7 |a MED  |x 071000  |2 bisacsh 
072 7 |a PBT  |2 bicssc 
245 0 0 |a Group-sequential clinical trials with multiple co-objectives /  |c Toshimitsu Hamasaki, Koko Asakura, Scott R. Evans, Toshimitsu Ochiai. 
264 1 |a Japan :  |b Springer,  |c 2016. 
300 |a 1 online resource (ix, 113 pages) :  |b illustrations 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
490 1 |a SpringerBriefs in statistics, JSS research series in statistics,  |x 2191-544X 
504 |a Includes bibliographical references. 
588 0 |a Online resource; title from PDF title page (SpringerLink, viewed June 13, 2016). 
505 0 |a 1. Introduction -- 2. Early Stopping for Efficacy in Clinical Trials with multiple co-primary endpoints -- 3. Sample size recalculation based on observed effects at interim -- 4. Early stopping for futility in Clinical Trials with multiple co-primary endpoints -- 5. Early stopping for futility or Efficacy in Clinical Trials with multiple co-primary endpoints -- 6. Clinical Trials with multiple primary endpoints -- 7. Group-sequential designs for three-arm noninferiority clinical trials -- 8. Further development: topics not covered in this book. 
520 |a This book focuses on group sequential methods for clinical trials with co-primary endpoints based on the decision-making frameworks for: (1) rejecting the null hypothesis (stopping for efficacy), (2) rejecting the alternative hypothesis (stopping for futility), and (3) rejecting the null or alternative hypothesis (stopping for either futility or efficacy), where the trial is designed to evaluate whether the intervention is superior to the control on all endpoints. For assessing futility, there are two fundamental approaches, i.e., the decision to stop for futility based on the conditional probability of rejecting the null hypothesis, and the other based on stopping boundaries using group sequential methods. In this book, the latter approach is discussed. The book also briefly deals with the group sequential methods for clinical trials designed to evaluate whether the intervention is superior to the control on at least one endpoint. In addition, the book describes sample size recalculation and the resulting effect on power and type I error rate. The book also describes group sequential strategies for three-arm clinical trials to demonstrate the non-inferiority of experimental intervention to actively control and to assess the assay sensitivity to placebo control. 
650 0 |a Clinical trials  |x Statistical methods. 
650 2 |a Clinical Trials as Topic  |x statistics & numerical data. 
650 7 |a MEDICAL  |x Pharmacology.  |2 bisacsh 
650 7 |a Clinical trials  |x Statistical methods.  |2 fast  |0 (OCoLC)fst00864440 
655 0 |a Electronic books. 
655 4 |a Electronic books. 
700 1 |a Hamasaki, Toshimitsu,  |e author.  |0 http://id.loc.gov/authorities/names/n2015190503 
700 1 |a Asakura, Koko,  |e author. 
700 1 |a Evans, Scott R.,  |e author.  |0 http://id.loc.gov/authorities/names/no96024663 
700 1 |a Ochiai, Toshimitsu,  |e author. 
776 0 8 |i Print version:  |a Hamasaki, Toshimitsu.  |t Group-Sequential Clinical Trials with Multiple Co-Objectives.  |d Tokyo : Springer Japan, ©2016  |z 9784431558989 
830 0 |a SpringerBriefs in statistics.  |p JSS research series in statistics.  |0 http://id.loc.gov/authorities/names/no2016036062 
903 |a HeVa 
929 |a oclccm 
999 f f |i 144bf752-f672-5abf-b5fe-e50dbb7063dd  |s 38853022-7a02-5802-adee-c172b513c55d 
928 |t Library of Congress classification  |a R853.C55  |l Online  |c UC-FullText  |u https://link.springer.com/10.1007/978-4-431-55900-9  |z Springer Nature  |g ebooks  |i 12537678